WilmerHale Advises Nabriva Therapeutics in Term Loan

WilmerHale Advises Nabriva Therapeutics in Term Loan

Firm News

Related Solutions

We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised Nabriva Therapeutics plc (NASDAQ:NBRVF), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, in an up to $75 million term loan with Hercules Capital, Inc. (NYSE:HTGC), $25 million of which was funded on the day of closing.

Brian Johnson and Jamie Class led the WilmerHale team representing Nabriva in this transaction, which also included Ellie Guadiana on credit matters and Scott Lunin and Alex Dzioba on corporate matters. 

Nabriva's announcement regarding the financing can be found at www.nabriva.com.

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel